Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Tags: Gastrointestinal Cancer News Source Type: news

Related Links:

Copyright © 2018 Cognizant Communication Corporation.
Oncol Res. 2018 Jun 21;:
Authors: Tang J, Li XY, Liang JB, Wu, Peng L, Li X
Abstract
Apatinib is an oral TKI with anti-angiogenesis properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an anti-angiogenesis agent has been shown to be feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical…

Source: Oncology ResearchCategory: Cancer & Oncology Tags: Oncol Res Source Type: research

This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or…

Source: DrugsCategory: Drugs & Pharmacology Source Type: research

Abstract
Leptomeningeal carcinomatosis (LMC) from gastrointestinal cancer is rare. A 56-year-old man with complaint of upper abdominal pain exhibited adenocarcinoma upon histopathologic examination of biopsy specimens. At the end of adjuvant chemotherapy, the patient was affected by hearing loss. Malignant cells were observed by cerebrospinal fluid (CSF) cytology. Therefore, the patient received intrathecal methotrexate and oral temozolomide chemotherapy and radiotherapy. The progress-free survival was approximately 11 months. To our knowledge, such cases of LMC from gastric cancer are very rare. Here, we describe…

Source: Cancer Biology and TherapyCategory: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research

ConclusionsThese data suggest that S-1/cisplatin and 5-FU/cisplatin are similar in efficacy and safety in untreated patients with advanced diffuse adenocarcinoma of the gastroesophageal junction or stomach. The primary end point was not met.ClinicalTrial.gov registration numberNCT01285557.

Source: Annals of OncologyCategory: Cancer & Oncology Source Type: research

Rationale: Osteosarcoma is the most common malignant bone tumor in children and adolescents. Pulmonary metastases lead to a significantly increased risk of death. Apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), shows survival benefits in treating advanced or metastatic gastric adenocarcinoma, non-squamous non-small cell lung cancer and metastatic breast cancer. However, its efficacy in metastatic osteosarcoma has not been reported yet.
Patient concerns: Herein, we presented a 50-year-old man patient who visi…

Source: MedicineCategory: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Purpose
We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma.

Patients and Methods
We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in which patients were randomly assigned at a two-to-one ratio and stratified by lines of prior chemotherapy for advanced disease (one v two) and region. Eligible patients received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred. The primary end point was …

Source: Journal of Clinical OncologyCategory: Cancer & Oncology Authors: Tags: Chemotherapy Gastrointestinal Cancer Source Type: research

The oral multikinase inhibitor regorafenib improves progression-free survival for patients with refractory advanced gastric adenocarcinoma, according to new research by Nick Pavlakis (University of Sydney, Sydney, NSW, Australia) and colleagues. The multinational, randomised phase 2 trial assessed 147 patients with gastric adenocarcinoma who had previous undergone chemotherapy. 97 patients were randomly assigned to supportive care plus regorafenib, and 50 patients were assigned to supportive care plus placebo.

Source: The Lancet OncologyCategory: Cancer & Oncology Authors: Tags: News Source Type: research

Purpose
There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety of apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom at least two lines of prior chemotherapy had failed.

Patients and Methods
This was a randomized, double-blind, placebo-controlled phase III trial. Patients from 32 centers in China with advanced gastric or gastroesophageal junction ade…

Source: Journal of Clinical OncologyCategory: Cancer & Oncology Authors: Tags: Chemotherapy, Rapid Communications, Rapid Communications Source Type: research

This report suggests clinicians should recognize this entity, even in gastric cancer metastatic to the liver.Case Rep Oncol 2016;9:106-111

In our Money Mic series, we hand over the podium to people with controversial views about money. These are their views, not ours, but we welcome your responses.

Today, one woman shares how an early-detection annual exam saved her life, and how the wise insurance decisions she made paid off — she only had a mere $100 tab for her entire treatment.

For all 44 years of my life, I’ve been diligent about my health.

I’ve never smoked, hardly ever drink, eat a healthy diet of mostly organic foods, and never forget my omega-3 supplements. I maintain a healthy weight, and lead an active lifestyle with my husband and two son…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image